Prostate cancer medicine hailed as a "milestone" breakthrough may not be available to every patient after a revision of the drug guidelines, according to the NHS.
Men in England who have already been treated with a new-generation cancer drug would not be eligible for Enzalutamide, according to the National Institute for Health and Care Excellence (Nice).
Nice, the public body which decides the cost-effectiveness of medicines for NHS patients, said the new drug should not be used by patients who had already taken abiraterone.
Enzalutamide blocks molecular signals driving prostate cancer and improved survival by 30% in men who had not undergone chemotherapy.
A further 80% of men with advanced cancer had the progression delayed, even if the tumour had failed to respond to other treatments.
More top news
It will be a wet start tomorrow for many but things are looking up for the afternoon.
The president of Sierra Leone has defended his reaction to the Ebola crisis, telling ITV News it will be contained by the end of the year.
James, who says police are stopping him on his walk to work because he looks like a fugitive, has started an internet campaign to buy a car.